Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK's Johnson warns lockdown, not vaccines, behind drop in COVID deaths

Tue, 13th Apr 2021 10:18

* Britain has offered shots to high-priority groups

* Johnson: lockdown largely behind lower cases

* PM cautions there will be more hospitalisations, deaths

* Moderna rollout begins in England

* Surge testing in London to track South Africa variant
(Recasts with Johnson, adds detail from health service)

By Alistair Smout and Sarah Young

LONDON, April 13 (Reuters) - British Prime Minister Boris
Johnson warned on Tuesday that the rapid drop in COVID-19 deaths
was largely down to a three-month lockdown, not the vaccination
programme, and that cases would rise once again as restrictions
ease.

The United Kingdom launched its inoculation drive in
December and has already offered a first shot to all over-50s,
the clinically vulnerable and health workers. The country is
behind only Israel in the proportion of its population to have
received at least one dose.

That rollout was however followed a month later by a third
lockdown in early January to tackle surging infections driven by
the "Kent" variant of the virus. Since February, daily infection
numbers, hospitalisations and deaths have all dropped sharply.

"The bulk of the work in reducing the disease has been done
by the lockdown," Johnson said on Tuesday, adding there was no
reason to change the roadmap for reopening the economy.

"As we unlock the result will inevitably be that we will see
more infections and sadly we will see more hospitalizations and
deaths."

With conditions improving, England reopened all retail,
hairdressers, gyms and pub gardens on Monday and Scotland,
Northern Ireland and Wales are due to reopen different elements
of their societies in the coming weeks.

The vaccine rollout also got a boost on Tuesday when Moderna
became the third vaccine to be offered in England after
AstraZeneca and one from Pfizer-BioNTech .

That will help keep Britain on track to hit its target of
offering all adults a vaccine by the end of July.

Moderna, already offered in the United States and Europe,
uses the same mRNA technology as Pfizer's shots but can be
stored at normal fridge temperatures unlike its rival U.S.
vaccine, which must be kept and shipped at ultra-low
temperatures.

On Tuesday, NHS England said that people aged 45 or over
could now book appointments to receive a COVID-19 vaccine.
For those categories already offered a vaccine, it said that 95%
of people who were eligible had taken up the offer.

However, in another note of caution to the optimism, the
government announced an expansion of so-called surge testing in
the south London boroughs of Lambeth and Wandsworth to detect
cases of the variant first found in South Africa.

There have been 74 confirmed and probable cases of the
coronavirus variant, known as B.1.351, in the boroughs, and
there is concern that vaccines are less effective against it.

"The important thing will be to watch: If the South African
variant has really taken off, and we'll probably know in about
two to three weeks, then we may need to pause re-opening a
little bit," James Naismith, professor of structural biology at
the University of Oxford and director of Rosalind Franklin
Institute, told BBC Radio.

With more than 127,000 fatalities, the United Kingdom has
the fifth-highest death toll in the world from COVID-19.
(additional reporting by Paul Sandle; Writing by Kate Holton;
Editing by Nick Macfie, Jon Boyle and Chizu Nomiyama)

More News
Today 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
Today 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
Today 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
Today 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.